Keyword: Akili Interactive
Akili Interactive is teaming up with Osaka-based Shionogi to help bring the first prescription digital therapeutics to Japan and Taiwan.
Akili Interactive licensed new software from UCSF that combines physical activity with programs targeting neural systems to cognitive function.
Akili brought its series C total up to $68 million while it awaits an FDA decision on its prescription video game for pediatric ADHD.
The Temasek-led series C round comes five months after Akili posted positive data from a pivotal clinical trial of its digital medicine.
Success against the primary endpoint in the pivotal trial sets Akili up to file for FDA approval of the digital medicine.
Alzeca Biosciences raised $11 million to develop its nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease.
Akili Interactive announced data showing its video game-based platform improved symptoms in children with sensory processing disorder.
Eddie Martucci co-founded Akili in 2011 alongside neuroscientist Adam Gazzaley and PureTech, with the goal of creating a brand-new type of medicine—“one that is truly enjoyable.”
Akili Interactive Labs and Pfizer present data showing Akili’s video game platform can differentiate between patients with and without brain amyloidosis.
Akili Interactive Labs, the Boston-based startup developing nonpharmacological therapeutics for various cognitive disorders like autism and Alzheimer’s disease, got an $11.9 million boost in funding, raising its total Series B proceeds to $42.4 million.